Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3901

Sigma-Aldrich

Crenolanib trifluoroacetate

≥98% (HPLC)

Synonym(s):

1-[2-[5-[(3-Methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine trifluoroacetate, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine trifluoroacetate, ARO 00 trifluoroacetate2, CP 868596 trifluoroacetate, CP868596 trifluoroacetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H29N5O2 · xC2HF3O2
Molecular Weight:
443.54 (free base basis)
MDL number:
MFCD21609260
UNSPSC Code:
12352200
NACRES:
NA.21

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Crenolanib is an orally bioavailable, potent and selective platelet-derived growth factor receptor (PDGFR) tyrosine kinase inhibitor. Also crenolanib potently inhibits FLT3.

Caution

Hygroscopic

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers
Journal of Clinical Oncology, 27(31), 5262-5269 (2009)
Activation of PDGFRA signaling contributes to filamin C-related arrhythmogenic cardiomyopathy
Science Advances, 8(8), eabk0052-eabk0052 (2022)
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors
Clinical Cancer Research, 18(16), 4375-4384 (2012)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service